Zibo, China – September 03, 2026 -- INTCO Medical (300677.SZ) reported revenue of 6.91 billion RMB (approximately $1.03 billion) for the six months ended June 30, 2026, up 40.61% year-on-year, as the company expanded its annual disposable glove production capacity to 107 billion units, cementing its position as the world's largest manufacturer in the category.

ZIBO, China – September 03, 2026 -- INTCO Medical (300677.SZ) reported revenue of RMB 6.91 billion (approximately USD 1.03 billion) for the six months ended June 30, 2026, up 40.61% year-on-year, as the disposable glove maker expanded annual production capacity to 107 billion units.

BEIJING -- Aug. 31, 2026 -- Walnut Coding placed No. 44 among 500 companies in TIME's World's Top EdTech Companies 2026 ranking, the only China-based youth coding education firm to break into the global top 100. The Beijing-founded company ranked sixth among 23 China-based firms on the list, which TIME compiled with market data provider Statista after screening roughly 6,500 education technology companies worldwide.

NEW YORK -- Aug. 31, 2026 -- Optimizely unveiled Virtual Teammates, a lineup of role-specific AI agents designed to work as persistent digital coworkers rather than one-off prompt tools, at its Opticon conference on Aug. 31, 2026.

MONTREAL -- September 01, 2026 -- Global Spatial Technology Solutions announced on Aug. 31, 2026 that it will change its corporate name to OCIANA, adopting the name of its flagship maritime intelligence platform. The Montreal-based company said the rebrand unifies its identity around a single product used by defense, security and maritime supply chain clients. All existing products, services and customer contact points remain unchanged under the new name.

Montreal -- September 01, 2026 -- Global Spatial Technology Solutions announced on Aug. 31, 2026 that it will now operate as OCIANA, unifying the company under the name of its flagship maritime intelligence platform. The rebrand covers all products, services and customer touchpoints, with GSTS.ca now redirecting to OCIANA.com. Richard Kolacz, chief executive of OCIANA, said the change marks the company's shift toward delivering maritime intelligence outcomes rather than only maritime domain awareness.

MONTREAL -- September 01, 2026 -- Global Spatial Technology Solutions (GSTS) announced on Aug. 31, 2026 that it is renaming itself OCIANA®, adopting the name of its flagship maritime intelligence platform. The Montreal-based company said the change unifies its corporate identity with the product customers already use. GSTS.ca began redirecting to OCIANA.com immediately, while products, services, and points of contact remain unchanged under the new name.

SOMERVILLE, Mass. -- September 01, 2026 -- Diffraqtion capped its pre-seed funding round at more than $10 million after Lockheed Martin Ventures and Presidio Ventures, the venture arm of Sumitomo Corporation, joined as strategic investors, the MIT and University of Maryland spinout announced Aug. 31, 2026. The Somerville, Massachusetts-based company builds quantum camera platforms for defense and space sensing.

Delray Beach, Fla. -- Aug. 31, 2026 -- The global transformer monitoring market will grow from $3.11 billion in 2026 to $4.98 billion by 2031, a 9.9% compound annual growth rate, according to MarketsandMarkets. The firm placed the 2025 market size at $2.84 billion. Utilities and industrial operators are driving the expansion by prioritizing transformer reliability and asset health as aging fleets and rising renewable integration strain existing grid infrastructure.

SOUTH SAN FRANCISCO, Calif. -- September 01, 2026 -- IDEAYA Biosciences said its FDA Type C meeting on IDE849, a DLL3-targeting antibody drug conjugate, produced agreement on a Phase 3 registrational trial design for extensive stage small cell lung cancer (ES-SCLC). The Nasdaq-listed company (IDYA) plans to enroll roughly 400 patients who have already received tarlatamab, randomizing them 1:1 between IDE849 monotherapy and an investigator's choice control arm of topotecan and amrubicin. IDEAYA is targeting trial initiation by year-end 2026.